Skip to content
by Legal Desire
18 September 2020

Allen & Overy advises Apax Partners and its portfolio company Neuraxpharm on the acquisition of Buccolam® Assets

Advising firms

Deal team

17 lawyers named
LawyerFirmSeniorityPracticeOffice
Paul Burns Lead A&O Shearman Partner Corporate and M&A Not stated
Caitlin Hanley A&O Shearman Associate Not stated New York
Lucy Cai A&O Shearman Associate Not stated New York
Matthew Appleton A&O Shearman Partner Corporate London
Jim Ford A&O Shearman Partner Corporate London
Gareth Irving A&O Shearman Counsel Not stated Not stated
Megan McMellon A&O Shearman Associate Not stated Not stated
Ben Brooks A&O Shearman Associate Not stated Not stated
Magnus Yadi A&O Shearman Associate Not stated Not stated
Marta Guardiola A&O Shearman Associate Not stated Madrid
Dominik Stühler A&O Shearman Partner Private Equity Munich
Kai Terstiege A&O Shearman Counsel Not stated Munich
Keren Livneh A&O Shearman Senior associate IP New York
Dr Heike Weber A&O Shearman Partner Tax Frankfurt
John Hibbard A&O Shearman Associate Tax New York
Dr René Galle A&O Shearman Counsel Antitrust Hamburg
Philipp Steinhaeuser A&O Shearman Associate Antitrust Not stated

14 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
Not stated
What the figure measures
Not stated
Client
Apax Partners and its portfolio company Neuraxpharm GroupBuy-side
Counterparties
Takeda Pharmaceutical Company Limited (Sell-side)